The Impact of Inflammatory Adhesion on the Prognosis of Colon Cancer Patients

November 6, 2024 updated by: Jianqiang Tang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

The Impact of Tumor-associated Inflammatory Adhesion on the Prognosis of Colon Cancer Patients: a Study Based on the SEER and Chinese Multi-center Databases

The purpose of this study is to explore the impact of tumor-associated inflammatory adhesion on the prognosis of colon cancer patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In some colon cancer patients, although adhesions between the tumor tissue and surrounding organs are found during surgery, postoperative pathology confirms that the tumor has not directly invaded the adhered organs; instead, the adhesions are caused by tumor-associated inflammation. This condition is defined as tumor-associated inflammatory adhesion.

Currently, the impact of tumor-associated inflammatory adhesion on patient prognosis is still unclear. This study aims to explore the impact of tumor-associated inflammatory adhesion on the prognosis of colon cancer patients through the Surveillance, Epidemiology, and End Results (SEER) and Chinese multi-center databases.

Study Type

Observational

Enrollment (Actual)

229

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This study utilized the Chinese multi-center database as well as the SEER 17 registries database. The Chinese multi-center database contains data of patients between January 2010 and December 2021, at 3 institutions. SEER*Stat software (version 8.4.1.1) was used for collecting 17 registries cohort data on patients diagnosed with NMIBC between 2010 and 2019.

Description

Inclusion Criteria:

  1. The patient was pathologically diagnosed as colon adenocarcinoma by endoscopic biopsy before operation.
  2. All patients were considered to have tumors invading adjacent organs during surgery
  3. All patients underwent radical surgery.

Exclusion Criteria:

1. Patients with distant metastasis, recurrent colon cancer and pT4b CRC were excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
the U.S. National Cancer Center SEER database
SEER*Stat software (version 8.4.3) collected 17 registries cohort data on colon cancer patients between 2010 and 2019.
Other: This was a retrospective study and no patient intervention was performed.
This was a retrospective study and no patient intervention was performed.
Chinese multi-center database
Chinese multi-center database includes patients from January 2010 to December 2021 at 3 institutions.
Other: This was a retrospective study and no patient intervention was performed.
This was a retrospective study and no patient intervention was performed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival time (OS)
Time Frame: up to 10 years
OS, defined as the time from the first diagnosis to death from any cause or the last follow-up for surviving patients
up to 10 years
Cancer-specific survival time (CSS)
Time Frame: up to 10 years
CSS refers to the duration from diagnosis of a tumor until the patient succumbs to the tumor, excluding deaths from other causes.
up to 10 years
Recurrence free survival time (RFS)
Time Frame: up to 10 years
RFS is the time from the time a patient achieved R0 resection after surgery to the time of recurrence or the end of follow-up.
up to 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 24, 2024

Primary Completion (Actual)

October 26, 2024

Study Completion (Actual)

October 27, 2024

Study Registration Dates

First Submitted

October 22, 2024

First Submitted That Met QC Criteria

October 22, 2024

First Posted (Actual)

October 23, 2024

Study Record Updates

Last Update Posted (Estimated)

November 7, 2024

Last Update Submitted That Met QC Criteria

November 6, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCC3650

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colon Cancer

Clinical Trials on This was a retrospective study and no patient intervention was performed.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe